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Abstract: Resistance to therapeutic agents and the highly toxic side effects of synthetic drugs has spurred new research in the treatment
of colon cancer, which has high morbidity and mortality ratios. This study aims to clarify the molecular mechanisms of the anticarcinogenic properties of methanol extract of Viburnum opulus L. (EVO)and its main active compound, trans-p-coumaric acid (p-CA),
on human colon cancer cells (DLD-1, HT-29, SW-620, Caco-2) and healthy colon epithelial cells (CCD-18Co). The effects of EVO on
controlled cell death (apoptosis) and the cell division cycle were determined by flow cytometry. Alteration in mRNA and protein expressions of switch genes in colorectal carcinoma (APC, MLH1, TP53, SMAD4, KRAS, and BRAF) were determined by qRT-PCR and
Western blot, respectively. Our results show that EVO possesses a strong reducing capacity and free-radical scavenging activity. HPLC
analyses prove that p-CAis the main compound of EVO. EVO and p-CA inhibit the proliferation of human colon cancer cells DLD-1
and HT-29 in a dose-dependent manner. EVO increases apoptosis of DLD-1 cells and halts the cell cycle in the G2 stage in HT-29 cells.
mRNA and protein expressions of p53 and SMAD-4 are upregulated, while BRAFs are downregulated. The results were directly proportional to p-CA. EVO and p-CA up- and downregulate switch genes and protein expressions of DLD-1 cells, which alter the expression
of 186 other genes. This is the first study of pharmacological exploration of V.opulus in human colon cancer. Its antiproliferative effects
may be due to the presence of p-CA.
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1. Introduction
Cancer is one of the leading causes of morbidity and
mortalityaround the world. According to the World Health
Organization’s 2015 data, the death rate from cancer has
reached 8.8 million, which is expected to increase by
70% over the next 20 years1. Colorectal cancer (CRC),
seen both in men and women, is the third most common
cause of death worldwide (Globocan, 2014). Many factors,
including inflammatory bowel disease, colon involvement,
epigenetic changes, and family history, are closely related
to the progression of CRC (Johnson et al., 2013). Increased
age and a lifestyle including high meat consumption, low
vegetable consumption, low physical activity, and high
alcohol and food consumption are major factors that
influence CRC development (Cunningham et al., 2010).
Molecular studies showed that CRC is under the control
1
WHO (2015). Cancer [online]. Website: http://www.who.int/
mediacentre/factsheets/fs297/en/ [accessed 30 July 2015].

of signaling pathways including Wnt/β-catenin, NF-κB,
Nrf2,and PI3K/Akt/mTOR, in which KRAS, BRAF, APC,
p53, and SMAD-4 possess crucial importance (Zhang et
al., 2015; Dawood et al., 2019; Sheng et al., 2019; Wang
et al., 2019). Mutations inAPC, MLH1, TP53, SMAD4,
KRAS, and BRAF genes play a crucial role in CRC
progression and are a reason for the increased incidence
of CRC (Namani et al., 2017). These genes interact with
a total of 184 genes; alteration of these genes affects the
progression of CRC.
Several chemotherapeutic drugs including cisplatin
have been implemented to treat CRC. Nevertheless, the
adverse effects of chemotherapy are connected to high
mortality and reactive oxygen species production (Wu et
al., 2019).Although surgery is the most effective treatment
method, postsurgery chemotherapy or radiotherapy is
required because of the high probability of recurrence
after surgery. It is necessary to seek new and alternative
treatment options to increase the survival rate in CRC.
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Therefore, identifying a new therapy to contend against
CRC is critically important. Plants synthesize hundreds
of secondary metabolites as a defense mechanism against
insects, fungi, various mammals, and many diseases.
However, the molecular mechanisms of those metabolites
require more investigation. There is a significant argument
for promoting the consumption of vegetables and
fruits, which contain plenty of antioxidants that defend
against illness and oxidative devastation (Celik et al.,
2016; Karakurt et al., 2016). The genus Viburnum L., a
member of the Adoxaceae family, consists of more than
230 species distributed in the temperate and subtropical
regions from South America to Southeast Asia. In
Turkey, the Viburnum genus is represented by 4 species:
V. lantana L., V. opulus L.,V. orientale Pall., and V. tinus
L. V.opulus possesses darkred edible fruits containing
high amounts of polyphenols such as chlorogenic acid,
catechin, epicatechin, and anthocyanins, and organic acids
such as ascorbic and oxalic acids (Cam and Hisil, 2007).
Thepolyphenols in V. opulus have also been used for the
synthesis of silver nanoparticles that have been used as
an antiinflammatory compound both in vitro and in vivo
(Moldovan et al., 2017). The fruits of V. opulus have been
traditionally used to treat some health problems such as
tension, bladder disturbances, duodenal ulcers, cough,
cold, kidney, and menstrual and stomach cramps in some
countries (Ezov and Koncejev, 2000; Moldovan et al.,
2012). It has been demonstrated that V. opulus, commonly
grownin central Anatolia, has protective functions against
urolithiasis and inflammation (Kizilay et al., 2019). V.
opulus extract presented anticancer properties in Ehrlich
ascites tumor-bearing mice (Ceylan et al., 2018). Colonic
lesions induced by 1,2 dimethylhydrazine were found to
beinhibited by V. opulus in the mouse colon (Ulger et al.,
2013). However, very few studies have examined the effects
of V. opulus on human colon cancer. Furthermore, the
molecular mechanism of action and the mechanism of cell
death have not been elucidated either in vivo or in vitro.
Following the o-oxygenation and methylation reactions
in plants, hydroxycinnamic acid derivatives including
p-coumaric and caffeic acid are produced (Russell and
Duthie, 2011). These phenolic compounds have a crucial
role in the scavenging of free radicals, the regulation of
gene and protein expression, xenobiotics metabolism and
cellular signaling related to apoptosis, cell proliferation,
and the DNA repair system. Anticarcinogenic properties
of p-coumaric against several human CRC cells such
as Caco-2, HT-29, and SW-480 have been investigated
in many studies (Janicke et al., 2011). Here, the in
vitro anticarcinogenic effects of V. opulus and its active
compound p-CA are compared.
In this study, we aim to investigate the cytotoxic effect
of EVO and p-CA on human colorectal cell lines including

DLD-1, HT-29, SW-620, and Caco-2 and to clarify the
molecular mechanisms.
2.Materials and methods
2.1. Chemicals
Trans-p-coumaric acid (55823) was purchased from Sigma
(Sigma-Aldrich, St. Louis, MO, USA), and 100 pmol of
primers were synthesized by BM Laboratory systems
(Ankara, Turkey). CCD-18Co cells (ATCC-CRL-145),
modified McCoy’s 5a medium(ATCC-30-2007), EMEM
(ATCC-30-2003),RPMI 1640 medium (ATCC-30-2001),
and fetal bovine serum (FBS; ATCC-30-2020) were
obtained from ATCC (American Tissue Culture Company,
Manassas, VA, USA). The SMAD4 (10231-1-AP), KRAS
(12063-1-AP), BRAF (20899-1-AP),and TP53 (10442-1AP) primary antibodies (1/1000 diluted) were purchased
from Proteintech (Proteintech Laboratories, Manchester,
UK). An apoptosis kit was obtained from BD Biosciences
(Woburn, MA, USA). Solvents were HPLC grade; all other
chemicals were of analytical grade.
2.2. Plant materials
The fruits of V. opulus were harvested from a cultivated
area in Kayseri, Turkey in September 2017. The plant
was identified by the authors, and voucher specimens
were placed in the Herbarium of Hacettepe University,
Faculty of Pharmacy, Ankara, Turkey under the number
HUEF17039.
2.3. Extraction
Fresh fruits (each 50 g) were extracted with methanol 3
times for 3 days and filtered. The concentrated extracts
were dried under reduced pressure at 40 °C and lyophilized.
2.4. High-performance liquid chromatography (HPLC)
analysis
2.4.1. Determination of individual phenolic compounds
by HPLC
The phenolic compounds of EVO were analyzed with a
Shimadzu LC-20AD HPLC system (Kyoto, Japan). Seventy
mg of methanol extract was diluted 40-fold with methanol
and filtered through a filter disk for HPLC analysis.
Separation of phenolic compounds was accomplished with
an Inertsil ODS-3V C18 column (GL Sciences Inc., Tokyo,
Japan) (5µm; 4.6 × 250 mm i.d.). The mobile phase flow
rate was kept at 1.0 mL/min. Mobile phase A was water
containing 0.05% gAc, and mobile phase B was acetonitrile.
The gradient conditions were as follows: 0–0.10 min, 8% B;
0.10–2 min, 8–10% B; 2–27 min, 10%–30% B; 27–37 min,
30%–56% B; 37–45 min, 56%–80% B. The temperature of
the column was controlled at 30 °C. The injection volume
was 20 μL. The phenolic compounds were monitored at
280 nm with an SPD-20A UV-Vis detector. The phenolic
compounds in EVO were identified by using authentic
standards and comparing with the standard compounds
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in terms of retention times and UV data. The quantitative
analysis of phenolic compounds was performed by use
of a calibration curve constructed for each commercial
standard, i.e. gallic acid, protocatechuic acid, catechin
hydrate, 4-hydroxybenzoic acid, caffeic acid, syringic acid,
rutin trihydrate, trans-p-coumaric acid, trans-ferulic acid,
trans-resveratrol, trans-cinnamic acid, and naringenin. The
standard phenolic compounds were dissolved in methanol;
8 different concentrations of each compound ranging from
1 to 65 ppm were prepared by diluting the stock solution.
Three injections were performed for each concentration
level, and the calibration curves were constructed by
plotting the peak area against concentration. The results
are expressed as ppm (parts per million).
2.4.2. Determination of organic acids by HPLC
The quantification of organic acids in EVO was carried
out with a Shimadzu LC-20AD HPLC system (Kyoto,
Japan). Sixty mg of methanol extract was diluted 20-fold
with water and filtered through a filter disk for HPLC
analysis. A MetaCarb 87H Column (300 × 7.8 mm; Agilent
Technologies, Santa Clara, CA, USA) coupled with a
MetaCarb 87H Guard Column (50 × 4.6 mm) was used
for separation at a flow rate of 0.6 mL/min.The mobile
phase was 0.1 N H2SO4. The organic acids were monitored
at 210 nm with the SPD-20A UV-Vis. The organic acids
in EVO were identified using the authentic standards and
comparing retention times and UV data with the standard
compounds. The quantitative analysis of organic acids was
achieved by use of a calibration curve constructed for each
commercial standard—i.e. citric acid, tartaric acid, maleic
acid, succinic acid, formic acid, acetic acid, and fumaric
acid. The standard compounds were dissolved in deionized
water; 6 different concentrations of each compound
ranging from 1 to 100 ppm were prepared by diluting
the stock solution. Three injections were performed for
each concentration level, and the calibration curves were
constructed by plotting the peak area versus concentration.
The results were expressed as ppm (parts per million).
2.5. Antioxidant activity
2.5.1. DPPH radical scavenging capacity assay
DPPH radical scavenging capacity assay was performed
according to a slightly modified version of the method
described by Brand-Williams et al. (1995). The extract
and the reference, dissolved in methanol at various
concentrations (150 µL), were mixed with 1 mM DPPH
solution in methanol (50 µL) and incubated for 30 min.
The change in absorbance was measured at 517 nm. The
DPPH radical scavenging capacity was calculated as given
below:
Inhibition % = [(Ablank−Asample)/Ablank]×100.
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Quercetin was used as a reference. Triplicate reactions
were performed. The scavenging capacity of the extract
was expressed as a half-maximal inhibitory concentration
(IC50).
2.5.2. Cupric ion reducing antioxidant capacity (CUPRAC) assay
The cupric ion reducing antioxidant capacity of EVO
was determined using the method of Apak et al. (2004)
with slight modifications. The reaction mixture contained
equal amounts of 10 mM of CuCl2 solution, 7.3 µM of
neocuproine solution, and 1 M of NH4Ac buffer solution
at pH 7.0. To make the final volume of 200 µL, 25 µL of
sample and 25 µL of distilled water were added to the
mixture. The final solution was incubated for 30 min at
RT (room temperature) and the samples were measured at
450 nm. The result was presented as gallic acid equivalent.
2.5.3. Determination of total phenolic contents
The total phenolic content of EVO was estimated according
to the method described by Slinkard and Singleton (1977)
using Folin-Ciocalteau’s reagent; 20 µL of extract dissolved
in ethanol and 7.5% (w/v) Na2CO3 solution were mixed
with Folin-Ciocalteau’s reagent(1:10). The reaction
mixture was incubated at RT for 2 h and measured at 765
nm. The result was presented as gallic acid equivalent.
2.5.4. Determination of total flavonoid contents
The total flavonoid content of EVO was determined by
using the aluminum chloride colorimetric method (Chang
et al., 2002). Twenty-five µL of thesamplewas mixed with
95% ethanol, 10% AlCl3, and 1 M KCH3COO. Following 30
min of incubation at RT, the absorbance was measured at
415 nm. The result was presented as quercetin equivalent.
2.6. Cell culture
Human CRC cell lines(DLD-1, HT-29, SW-620,Caco-2)
and human colon fibroblast cell line CCD-18Co were
cultivated in RPMI-1640, McCoy’s 5a, Leibovitz’s L-15,
and EMEM growth mediums (ATCC), respectively and
supplemented with 2 mM L-glutamine (Sigma-Aldrich),
10% fetal bovine serum (FBS), and 1% penicillin/
streptomycin at 37°C in 5% CO2 at 90%–95% humidity.
2.6.1. Cell viability assay
1 ×104 cells were seeded into a 96-well plate with growth
medium and incubated at 37 °C in 5% CO2 for 24 h until
the cells attached to the bottom. The cells were then treated
with various concentrations of EVO ranging from 1 µg/
mL to 1000 µg/mL and p-CA ranging from 0 to 1000 µM.
The cell viability and proliferation were measured through
the Alamar Blue assay (Karakurt and Adali, 2016). The
absorbance was measured at 570 nm and 610 nm using
a multiwell scanning spectrophotometer (Multiskan Go;
Thermo Scientific Co., Waltham, MA, USA). IC50 values of
EVO were calculated from the sigmoidal plot of inhibition
ratio (%) vs. log EVO concentration.
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2.7. Apoptosis assay
30 × 104of DLD-1 cells were seeded into a 6-well plate and
treated with an equivalent IC50 concentration of EVO and
p-CA and incubated for 48 h at 37 °C in 5% CO2. Trypsinized
and washed (with 10 mM PBS) cells were double-stained
with FITC Annexin V and 7-Aminoactinomycin D (7AAD). The effects of EVO on the percentage of DLD-1
and HT-29 cells which had undergone apoptosis and
necrosis were determined according to the manufacturer’s
instructions (BD Bioscience, San Jose, CA, USA). Early
apoptotic, late-stage apoptotic, or necrotic cells were
examined using a NovoCyte flow cytometer (Acea
Biosciences Inc, San Diego, CA, USA).
2.8. Cell cycle analysis
15 × 104 of DLD-1 cells were seeded into a 6-well plate and
treated with the equivalent IC50 concentration of EVO and
p-coumaric acid, and then harvested by trypsinization.
After fixation in 70% ice-cold ethanol for 2 h, the cell
pellets were incubated with 100 μg/mL of RNase A and
50 μg/mL of PI for 30 min. Using the NovoCyte flow
cytometer, 50,000 cells from each group were subjected to
cell cycle analysis.
2.9. Preparation of cell lysates and Western blot analysis
30 × 104of DLD-1 cells were seeded into 100 cm2 Petri
dishes and treated with the equivalent IC50 concentration
of EVO and p-coumaric acid. Following the incubation,
the cells were washed with pre-cold PBS and lysed in RIPA
buffer (Cell Signaling Technology, Beverly, MA, USA) with

1 mM of PMSF. The lysates were centrifuged at 14,000 g at
4°C for 15 min. The supernatant was used to determine the
protein concentration, which was determined by the BCA
method. Fifteen µg of the protein samples were separated
by SDS-PAGE (4% stacking gel and 7.5% separating
gel), blotted onto PVDF membrane, and incubated with
polyclonal (rabbit) anti-APC, anti-TP53, anti-BRAF, antiSMAD4, anti-KRAS antibodies (Bio-Rad Laboratories,
Hercules, CA, USA) overnight at 4°C, and with goat antirabbit IgG secondary antibody for 1 h at RT. ECL detection
systems (Thermo Scientific Co.) were used for detection.
Gels were photographed using the Syngene GBOX Chemi
XRQ imaging system (Frederick, MD, USA) and analyzed
using the GeneSys software.
2.10. Total RNA isolation, cDNA synthesis, and qRTPCR analysis
The total RNA of DLD-1 cells was extracted using QIAzol
Lysis Reagent (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Quantity and quality of total
RNA were measured using an Agilent 2100 Bioanalyzer,
and samples with higher RIN (>7) were used for the
synthesis of cDNA. cDNA was synthesized from 1 ng
of total RNA via reverse transcription using an iScript
Reverse Transcription cDNA synthesis kit according to
the manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA). The synthesized cDNAs were
subjected to amplification using specific primers that
were designed as shown in Table 1. The expression of

Table 1. Primer sequence of colorectal cancer progression key genes.
Gene

NCBI reference
number

APC

NM_001127510.3

MLH-1

NM_000249.4

TP53

NM_001276696.2

SMAD4

NM_005359.6

KRAS

NM_001369786.1

BRAF

NM_001374258.1

GAPDH NM_001357943.2

Sequences (5’à3’)
F- TGAGGCACTGAAGATGGAGA
R- TCTGTCCAGAAGAAGCCATAG
F- TGTTAAAGAGGGAGGCCTGA
R- CTCACCTCGAAAGCCATAGG
F- CACATGACGGAGGTTGTGAG
R- TAGGGCACCACCACACTATG
F- CACAGGACAGAAGCCATTGA
R- ACGCCCAGCTTCTCTGTCTA
F- TGCAATGAGGGACCAGTACA
R- TCCTGAGCCTGTTTTGTGTCT
F- TCAACCACAGGTTTGTCTGC
R- TCACTCGAGTCCCGTCTACC
F-AATCCCATCACCATCTTCCA
R-TGGACTCCACGACGTACTCA

Annealing
temp. (°C)

PCR product size
(base pair)

60

158

60

157

60

158

60

150

60

201

60

164

60

82
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GAPDH was used as a reference gene, which was used
as an internal control for normalization. qRT-PCR was
accomplished with a CFX Connect Real-Time PCR
Detection System with the optical 96-well plate (Bio-Rad
Laboratories). Twenty μL of the reaction mix containing
10 μL SYBR GREEN PCR Master Mix, 2 μL diluted cDNA
template, and 0.4 μL of each primer was added into each
well. The thermal cycling profile was recommended by the
manufacturer: 98 °C for 30 s, 40 cycles at 98 °C for 15 s,
60 °C for 30 s. To confirm the specificity of the primers,
melting curves were included after amplification. All
reactions were run in triplicate, and the fold-change of
mRNA expression was calculated according to the delta
delta (2[−ΔΔCt]) method.
2.11. Statistics
Each experiment was repeated at least 3 times. Quantitative
data were processed with GraphPad Prism (GraphPad
Software v5.0, San Diego, CA, USA). Results are represented
as mean ± SD. Statistical comparisons between groups
were made using two-way repeated measure analysis of
variance (ANOVA) and two-tailed Student’s t-test, where
P < 0.05 was considered to be statistically significant.
3. Results and discussion
V.opulus (Figure 1a) was subjected to methanol extraction,
andthe phenolic content of EVO was determined by
HPLC. Depending on the type of solvent, HPLC-UV
chromatograms of EVO may show quite different profiles
due to the structural dissimilarity of the solvents. When
these solvents were compared, EVO displayed the highest
amount of phenolic/flavonoid compounds as well as the

highest antioxidant activity, while water and acetonitrile
extracts of V. opulus possessed a low amount of phenolic
compounds and lowantioxidant activity (Karacelik et al.,
2015). The chromatogram of EVO after the derivatization
is shown in Figures 1b and 1c. The peaks of phenolic
compounds and organic acids were detected in the
chromatogram, and the composition of EVOis listed in
Table 2. As shown in Table 2, EVO contains a high amount
of p-CA (280.5 ± 10.8 ppm) and catechin hydrate (235.9
± 5.8 ppm), as well as citric acid (1198.1 ±16.9 ppm) and
formic acid (349.6±5.1ppm).
Catechin hydrate significantly inhibited the
proliferation of human cervical and breast cancer cell
lines with IC50 values of 196.07 μg/mL and 127.62 μg/mL,
respectively (Alshatwi, 2010; Al-Hazzani and Alshatwi,
2011).Citric acid,a well-known antioxidant compound,
prevents the oxidation of macromolecules via scavenging
reactive oxygen species (ROS). Citric acid treatment in
the range of 400–1600 µg/mL was found to increase the
cell apoptotic index (Chen et al., 2017). Karacelik et al.
(2015) also showed that EVO possesses rutin, epicatechin,
catechin, procyanidin B2, procyanidintrimer, and
proanthocyanidin dimer monoglycoside. In addition,
Velioglu et al. (2006) reported the concentrations of
catechin and quercetin in EVO as 290.4 mg/kg and 52.1
mg/kg, respectively. p-CA possesses anticarcinogenic
effects on human colon and cervical cancers and has been
demonstrated to inhibit the proliferation of HT-29 and
SW-480 cells (Sharma et al., 2018). Furthermore, EVO
contains a limited amount of organic acids in which citric
acid induces apoptosis via the mitochondrial pathway
(Ying et al., 2013).

Figure 1. HPLC fingerprint profile of EVO. a) Images of V. opulus. b) Determination of phenolic compound content of EVO at 280 nm:
1. Gallic acid (6.33 min); 2. Protocatechuic acid (10.05 min); 3. Catechin hydrate (12.81 min); 4. 4-Hydroxybenzoic acid (14.09 min); 5.
Caffeic acid (15.89 min); 6. Syringic acid (16.50 min); 7. Rutin trihydrate (20.24 min); 8. p-CA (21.19 min); 9. Trans-ferulic acid (23.20
min); 10. Trans-resveratrol (31.34 min); 11. Naringenin (36.41 min). c) Organic acid content of EVO at 210 nm: 12. Citric acid (9.02
min); 13. Maleic acid (12.5 min); 14. Formic acid (15.2 min); 15. Fumaric acid (18.6 min). d) Structure of p-CA.
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Table 2. Phenolic and organic acid compositions of EVO
identified by HPLC.
Peak
RT
Compound
number (min)
1
6.33 Gallic acid

The mean ± SD of
concentration (ppm)
0.8 ± 0.02

2

10.05 Protocatechuic acid

18.5 ± 1.90

3

12.81 Catechin hydrate

235.9 ± 5.80

4

14.09 4-Hydroxybenzoic acid 41.7 ± 3.40

5

15.89 Caffeic acid

5.2 ± 1.20

6

16.50 Syringic acid

3.4 ± 0.20

7

20.24 Rutin trihydrate

13.1 ± 0.20

8

21.19 Trans-p-coumaric acid 280.5 ± 10.80

9

23.20 Trans-ferulic acid

1.2 ± 0.05

10

31.34 Trans-resveratrol

0.4 ± 0.01

11

36.41 Naringenin

20.3 ± 1.20

12

9.02

Citric acid

1198.1 ± 16.90

13

12.5

Maleic acid

1.2 ± 0.20

14

15.2

Formic acid

349.6 ± 5.10

15

18.6

Fumaric acid

0.73 ± 0.10

SD: Standard deviation; RT: Retention time; ppm: Parts per
million; min: Minutes.

EVO was then evaluated for the antioxidant capacity
using the DPPH and CUPRAC assays as shown in Table
3. The plant extract was found to have concentrationdependent inhibitory activity against DPPH radicals.
The inhibition percentages of EVO on DPPH radical
were 24.53 ± 0, 30.02 ± 0.34, 43.02 ± 1.74, 61.14 ± 1.98,
and 89.99 ± 0.78 at 25, 50, 100, 200, and 400 µg/mL
concentrations, respectively.The IC50 value for the DPPH
radical scavenging capacity of EVO was 156.51 ± 1.12
µg/mL. Cupric ion reducing antioxidant capacity of the
plant extract was determined as 44.06 ± 1.55 gallic acid
equivalent (mg/g extract). Altun et al. (2008) investigated
the antioxidant properties of the water extracts prepared
from the different parts of V. opulus. Fruit extract showed
DPPH scavenging activity with an IC50 value of 57 µg/
mL. The total phenolic content was determined according

to the equation obtained from the gallic acid standard
curve(y=0.0074x+0.1064; R2=0.9957), whereas the total
flavonoid content was calculated according to the equation
obtained from the quercetin standard curve (mg/g extract)
(y=0.0043x+0.0588; R2=0.9991). The total phenolic content
of EVO was calculated as 310.07 ± 2.20 mg GAE/g extract,
and the total flavonoid content was found to be 5.86±
0.40 mg QE/g extract. In a previous study, total phenolic
contents of the fresh and pasteurized fruit juices of V. opulus
were 351.26 ± 27.73 and 330.40 ± 29.46 mg GAE/100 mL,
respectively (Cam and Hisil, 2007). Furthermore, Karacelik
et al. (2015) investigated the antioxidant activity of the
fruit juice and methanol, acetonitrile, and water extracts
prepared from seeds and peels, separately. They found
the highest activity in fruit juice (2.5-fold more than our
result). In this study, we made methanol extract without
separating the fruit parts; therefore, it is understandable
that their results were higher than ours. After the
determination of characteristic properties of EVO, we
examined the antiproliferative activity of EVO and p-CA
against human colorectal carcinoma cells (DLD-1, HT29, SW-620, and Caco-2), and human colon epithelium
cell (CCD-18Co). The Alamar Blue assay was performed,
and the cells were treated with EVO and p-CA for 48 h.
As shown in Figure 2a, EVO significantly and selectively
inhibited proliferation of DLD-1, HT-29, SW-620, and
Caco-2 cells, with IC50 values of 254.3 µg/mL, 553.3 µg/
mL, 327.4 µg/mL, 714,6 µg/mL, respectively (P < 0.0001).
EVO and p-CA inhibited the proliferation of DLD-1 and
HT-29 cells in a dose-dependent manner. The genetic and
molecular mechanisms in cancerous cells are different
from each other. Therefore, these cells possess different
behaviors against chemical agents. The cells of SW-620
are the strongest Wnt signal followers, while DLD-1 is the
lowest. Maximum inhibitory action was found on DLD-1
cells. We investigated the antiproliferative effects of p-CA
on this cell line, and the IC50 value of p-CA on DLD-1 cell
was calculated as 223 µM (Figure 2b). It was also proven
that p-CA inhibited HT-29 and Caco-2 cells with IC50
values of 1.5 mM and 1.6 mM, respectively (Jaganathan et
al., 2013). On the other hand, the viability of healthy colon
epithelium cells (CCD-18Co)were slightly inhibited after

Table 3. Antioxidant capacity, total phenolic and flavonoid content of EVO.

Sample

DPPH radical scavenging
CUPRAC value ± SD Total phenolic content ± SD Total flavonoid content ± SD
capacity, the mean ± SD of
(mg GAE/g extract) (mg GAE/g extract)
(mg QE/g extract)
the IC50 value (µg/mL)

EVO

156.51 ± 1.12

Quercetin 12.04 ± 0.87

44.06 ± 1.55

310.07 ± 2.20

5.86 ± 0.40

-

-

-

SD: Standard deviation; GAE: Gallic acid equivalent; QE: Quercetin equivalent.
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EVO and p-CA treatment in which IC50 was theoretically
calculated (>2 mg/mL) from the sigmoidal plot as 2117 µg/
mL and 1.6 mM, respectively (Figure 2b). Figures 2c and
2d show that EVO and p-CA have cytotoxic potential on
the growth of DLD-1 cells and inhibited the proliferation
of the cells in a dose-dependent manner. EVO contains
a high amount of p-CA, which possesses carboxylic and
phenolic OH groups, and catechin hydrate, which possesses
phenolic OH groups. The carboxylic group is much more
acidic than phenolic OH and may protonate the enzymes
and DNA, whereas the phenolic OH makes a hydrogen
bond with the enzymes and DNA. Bioflavonoids have
broad anticancer characteristics based on their capability
to promote differentiation and apoptosis, blockade of
cellular carcinogen induction, cellular proliferation, tumor
cell adhesion, and angiogenesis (De Kok et al., 2008). Some
chemotherapeutic compounds have high cytotoxicity at
low concentrations. However, these compounds have very

limited utility because they can damage healthy cells as
well as cancerous cells (Evdokiou et al., 2002; Beijers et
al., 2012). Therefore, it is very important to determine the
dose that affects cancerous cells but does not affect healthy
cells in dose selection. The IC50 value of EVO was 254.3 µg/
mL for human colorectal carcinoma cell line DLD-1, while
it was more than 2 mg/mL for the healthy human colon
epithelial cell line, CCD-18Co. Moderate cytotoxicity and
safe concentration of EVO seem in balance for colorectal
cancer treatment.
To clarify the molecular mechanism of the inhibition
effect of tumor cell (DLD-1) growth by EVO, the cell
cycle and apoptosis were examined by ﬂow cytometry.
Following treatment with 254 µg/mL of EVO for 48 h, the
EVO groups exhibited statistically significant differences
in cell cycle compared with the NT(nontreated) groups.
A cell-cycle arrest at the G2/M checkpoint with an
accumulation of cells in the G2 phase was observed.

Figure 2. The effects of EVO and p-CA on the proliferation of human CRC cells; Caco-2, DLD-1, HT-29, SW-620 and healthy colon epithelium cell; CCD-18Co cells. a) Effects of EVO and p-CA on the proliferation of human CRC cells measured by Alamar Blue assay. b)
IC50 values were determined sigmoidal plot of cell viability vs. log EVO (µg/mL) and log p-CA (µM) concentration. c) Heat map analyses
of dose-dependent inhibition of EVO and p-CA against DLD-1 cells. Cell viability was decreased from red to blue color. d) Effects of
EVO and p-CA on the growth of DLD-1 cells were monitored by automated cell counter. The results shown are representative of three
independently performed experiments. NT: Nontreated; ***: P < 0.001; g: µM.
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Following the treatment with EVO, the proportion of
cells in the G2 phase and Freq Super-G2 decreased (1.7fold) and the percentage of cells in Freq Sub-G1 increased
significantly compared with the NT group (1.24% and
0.54%, respectively) (Figures 3a–3b). Increased Sub-G1
accumulation of DLD-1 cells confirmed the apoptosis.
p-CA was also demonstrated to increase Sub-G1 and G2
phases in Caco-2 and HT-29 cells. Herein, we started
to investigate the effects of EVO on apoptosis (Figures
3c–3d).The 48-h EVO treatment induced apoptosis 70%

higher than in the control group. The apoptotic and
necrotic rates in the NT group were as follows: necrosis
2.72%; late apoptosis 5.86%; early apoptosis 4.45%; live
cells 86.97%. In the EVO-treated group, the rates were
as follows: necrosis 5.42%; late apoptosis12.18%; early
apoptosis 5.70%; live cells 76.70%. Thelate apoptosis of
DLD-1 cells was significantly increased, which proved that
the membrane integrity of the DLD-1 cell was disrupted
and that the nucleus was released from the cell. It was
also proven that p-CA treatment increased the apoptotic

Figure 3. Representative cell cycle and apoptosis profile of DLD-1 cells determined by flow cytometer. a) and c) Cell cycle and apoptosis
analyses of nontreated (NT) group, b) and d) EVO treated group (n = 3). DNA was stained with PI and 7-AAD for cell cycle and apoptosis analyses, respectively.
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cell rate in DLD-1 cells. On the other hand, the apoptotic
rates did not significantly change in HT-29 cells. To clarify
the molecular mechanism of EVO on the proliferation
of human colorectal carcinoma cells, we investigated the
protein expression of key enzymes in signal transduction
pathways including TGFβ, WNT, MAPK, PI3K-Akt,
and p53 signaling pathways (Figure 4). Following the
treatment of equivalent EVO concentration with IC50,
protein expression of tumor suppressor p53and SMAD4
were significantly increased [1.43-fold (P < 0.0001)
and 1.39-fold (P = 0.0011), respectively]. In CRC, the
modulation of the p53 protein level is commonly seen;
its landmark sign and relation with clinicopathological
properties are still doubtful. Although some studies have
reported no relationship between p53 protein levels
and clinicopathological properties, some studies have
indicated that p53 expression is related to the metastatic
period (Aladhraei et al., 2019). Nevertheless, Cao et al.
(2017) stated that the lack of p53 expression was reported
in CRC tumors and related to a worse clinicopathological
response ,including lymph node metastasis and progressive
tumor development, because over 50% of human cancers
present defects of function mutations in TP53gene.
Hence, our results revealed that the protein expression
of p53 in CRC cells was increased by the administration
of EVO, which might provide a beneficial effect against
CRC progression. The TGF-β1 induction promotes the
activation of SMADs signalization. Previous studies have
demonstrated that TGFβ signaling induced cancer cell
proliferation, invasion, and metastasis, and blockade of
TGF-β1 inhibits metastatic cancer development. Thus, the

linkage of TGF-β1 inhibition that was used for the therapy
of CRC has an immediate need to be clarified (Massague,
2008). According to our results, the protein expression of
SMAD4 was found to be 1.39-fold higher than that of the
control group. Jiang et al. (2018) reported that celastrol is
an efficient drug which considerably prevented the mRNA
and protein expression of SMAD4 in CRC cells. SMAD4,
frequently deficient in CRC, has a role at the G1/S cell cycle
in stopping cells waiting in the G1 cycle, hence resulting
in cell cycle arrest (Zhao et al., 2018). Furthermore, the
treatment of CRC cells with EVO resulted in higher mRNA
and protein expression of SMAD4. This can be considered
a protective effect of EVO. Thus, the elevation of SMAD4
induces CRC cells to stop the cell cycle on the G1 phase,
which may lead to tumor suppression. BRAF has a pivotal
function in cell trafficking as a positive modulator within
the MAPK cascade. RAF is a member of the RAS––RAF–
MEK–ERK cell-signaling cascade, with a central function
in regulating cellular differentiation, proliferation, aging,
and survival against extracellular indications (Caronia et
al., 2011). BRAF expression was elevated in terminal stage
CRC patients compared to early-stage CRC patients (P
= 0.080) ( Kwon et al., 2018). It was found that pituitary
adenomas possess the highest levels of BRAF mRNA and
protein expressions (Ewing et al., 2007). Endometrial cells
expressed 2.4-fold higher BRAF activity compared with
the control cells and therefore caused abnormal activation
of RAS/RAF/MAPK signaling (Yotova et al., 2011). The
EVO treatment significantly decreased (21%; P = 0.014)
the BRAF protein expression when compared with the
control group. Thus, according to our findings, BRAF

Figure 4. Effects of EVO on protein expression of key proteins in signaling pathways in colorectal carcinoma. a) Immunoblot bands of
DLD-1 protein in nontreated (NT) and EVO groups. b) Quantitative band density analysis of the NT and EVO groups. Experiments
were repeated at least 3 times (n = 6). (*: P = 0.0140), (**: P = 0.0011) and (***: P < 0.0001) signify a statistically significant difference.
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protein expression may be diminished in CRC cells via
EVO.
To understand the origin of the alteration in the
protein expressions, we investigated the mRNA expression
of TP53, BRAF, KRAS, SMAD4, APC, and MLH genes
(Figure 5). mRNA expression of tumor suppressor
genes TP53 and SMAD4 were significantly (P < 0.0001)
increased 1.54-fold and 3.03-fold, respectively. On
the other hand, the mRNA expression of BRAF was
significantly (P < 0.0001) decreased (41%) after the EVO
treatment. Previous research has demonstrated that
SMAD4 is profoundly related to the progression of colon
metastases, and has a critical antimetastatic role in colon
cancer metastasis (Yan et al., 2018). Sheng et al.(2019)
reported that MiR-144 blocks the invasion of human colon
cancer cells. The transfected SW620 colorectal carcinoma
cells demonstrated lower SMAD4 expression. They also
reported that SMAD4 is detected in 30%–40% of theCRC
cases in the study, appearing in late stages in adenoma-tocarcinoma progression and resulting in liver metastases;
these cases have a worse outcome with chemotherapy
followed by a bad prognosis. In our study, SMAD4 was
found to be elevated. The SMAD4 tumor suppressor gene
product reduces TGF-β-mediated signaling and is defective
in ~10% of CRC. Chang et al. (2019) concluded that with
the help of targeted exome sequencing, higher deletion
proportions of MSH3, MSH6, APC, and PIK3CA were
found. They reported a significant role in CRC and found
common deletions in RAF (9.38%), APC (59.38%), TP53
(50%), RAS (28.13%), and SMAD4 (9.38%).In addition to
tumor suppressors and oncogenes, mRNA expression of
DNA repair enzyme MLH1 and WNT signaling pathway
regulator gene APC were also significantly inhibited
(44% and 40%, respectively) with the EVO treatment.
APC is commonly called a tumor suppressor gene, with
a higher incidence of deletion in CRC. APC is disordered
at both the germline and somatic steps (Zhang and Shay,
2017). The results of protein and mRNA expressions were
evaluated together; the reason for the alteration of protein
expressions seems to be the alteration in the mRNA
expressions.

Figure 5. Effects of EVO on the mRNA expression of signal
transduction key enzyme-coding genes; TP53, BRAF, KRAS,
SMAD4, APC, and MLH of DLD-1 cells. Alterations in mRNA
expressions were evaluated by qRT-PCR. Results were as relative
mean ± SD (n = 4). As a housekeeping gene GAPDH were used.
Fold change was calculated by 2-∆∆Ct. Groups were statistically
analyzed with Student’s t-test. ***: P < 0.00.

main active compound, p-CA, against human colorectal
carcinoma. Both significantly inhibited the proliferation of
human CRC line DLD-1, while no significant effects were
observed against healthy colon cells. EVO and p-CA up-/
downregulated CRC switch gene and protein expressions.
Modulation of these genes affects 186 other genes which
have crucial roles in TGF-β, MAPK, Wnt, and PI3KAkt signaling pathways. Additionally, EVO and p-CA
significantly increased apoptosis by altering Bax and Bcl2. Therefore, EVO and its active compound p-CA may be a
promising therapeutic agent against CRC.
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4. Conclusion
In this study, we clarify the molecular mechanism of
the cytotoxic effects of medicinal herb V. opulus and its
References
Aladhraei M, Al-Salami E, Poungvarin N, Suwannalert P (2019).
The roles of p53 and XPO1 on colorectal cancer progression in
Yemeni patients. Journal of Gastrointestinal Oncology 10 (3):
437-444. doi: 10.21037/jgo.2019.01.17.

Al-Hazzani AA, Alshatwi AA (2011). Catechin hydrate inhibits
proliferation and mediates apoptosis of SiHa human cervical
cancer cells. Food and Chemical Toxicology 49 (12): 32813286. doi: 10.1016/j.fct.2011.09.023.

261

KARAKURT et al. / Turk J Biol
Alshatwi AA (2010). Catechin hydrate suppresses MCF-7
proliferation through TP53/Caspase-mediated apoptosis.
Journal of Experimental & Clinical Cancer Research 29: 167.
doi: 10.1186/1756-9966-29-167.

Dawood M, Ooko E, Efferth T (2019). Collateral sensitivity of
parthenolide via NF-kappaB and HIF-α inhibition and
epigenetic changes in drug-resistant cancer cell lines. Frontiers
in Pharmacology 10: 542. doi: 10.3389/fphar.2019.00542.

Apak R, Guclu K, Ozyurek M, Karademir SE (2004). Novel total
antioxidant capacity index for dietary polyphenols and
vitamins C and E, using their cupric ion reducing capability
in the presence of neocuproine: CUPRAC method. Journal
of Agricultural and Food Chemistry 52 (26): 7970-7981. doi:
10.1021/jf048741x.

De Kok TM, Van Breda SG, Manson MM (2008). Mechanisms
of combined action of different chemopreventive dietary
compounds: a review. European Journal of Nutrition 2: 51-59.
doi: 10.1007/s00394-008-2006-y.

Beijers AJ, Jongen JL, Vreugdenhil G (2012). Chemotherapy-induced
neurotoxicity: the value of neuroprotective strategies. The
Netherlands Journal of Medicine 70 (1): 18-25.

Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S et al. (2002).
Chemotherapeutic agents sensitize osteogenic sarcoma cells,
but not normal human bone cells, to Apo2L/TRAIL-induced
apoptosis. International Journal of Cancer 99 (4): 491-504. doi:
10.1002/ijc.10376.

Brand-Williams W, Cuvelier ME, Berset C (1995). Use of a free radical
method to evaluate antioxidant activity. Food Science and
Technology 28 (1): 25-30. doi: 10.1016/S0023-6438(95)800085.

Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M et al.
(2007). A mutation and expression analysis of the oncogene
BRAF in pituitary adenomas. Clinical Endocrinology 66 (3):
348-352. doi: 10.1111/j.1365-2265.2006.02735.x.

Cam M, Hisil Y (2007). Comparison of chemical characteristics
of fresh and pasteurised juice of gilaburu (Viburnum
opulus L.). Acta Alimentaria 36 (3): 381-385. doi: 10.1556/
AAlim.362007.3.10.

Ezov LA, Koncejev MG (2000). Vse o jagodach –Novaja enciklopedia
dacnika. 1st ed. Moscow, Russia: Ripoll Klasik, pp. 311-387.

Cao DZ, Ou XL, Yu T (2017). The association of p53 expression levels
with clinicopathological features and prognosis of patients
with colon cancer following surgery. Oncology Letter 13 (5):
3538-3546. doi: 10.3892/ol.2017.5929.
Caronia LM, Phay JE, Shah MH (2011). Role of BRAF in thyroid
oncogenesis. Clinical Cancer Research 17 (24): 7511-7517. doi:
10.1158/1078-0432.CCR-11-1155.
Celik G, Semiz A, Karakurt S, Gencler-Ozkan AM, Arslan S et al.
(2016). Inhibitory action of Epilobiumhirsutum extract and
its constituent ellagic acid on drug-metabolizing enzymes.
European Journal of Drug Metabolism and Pharmacokinetics
41 (2): 109-116. doi: 10.1007/s13318-014-0238-1.
Ceylan D, Aksoy A, Ertekin T, Yay AH, Nisari M et al. (2018). The
effects of gilaburu (Viburnum opulus) juice on experimentally
induced ehrlich ascites tumor in mice. Journal of Cancer
Research and Therapeutics 14 (2): 314-320. doi: 10.4103/09731482.181173.
Chang CC, Yang MH, Wen HM, Chern JC (2002). Estimation of
total flavonoid content in propolis by two complementary
colorimetric methods. Journal of Food and Drug Analysis 10
(3): 178-182.
Chang YS, Lee CC, Ke TW, Chang CM, Chao DS et al. (2019).
Molecular characterization of colorectal cancer using wholeexome sequencing in a Taiwanese population. Cancer Medicine
8 (8): 3738-3747. doi: 10.1002/cam4.2282.
Chen X, Lv Q, Liu Y, Deng W (2017). Effect of food additive citric acid
on the growth of human esophageal carcinoma cell line EC109.
Cell Journal 18 (4): 493-502. doi: 10.22074/cellj.2016.4716.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B et al. (2010).
Colorectal cancer. Lancet 375 (9719): 1030-1047. doi: 10.1016/
S0140-6736(10)60353-4.

262

Globocan (2014). Estimated cancer incidince, mortality and
prevalence worldwide in 2012. IARC Cancer Base No:11.
Jaganathan SK, Supriyanto E, Mandal M (2013). Events associated
with apoptotic effect of p-coumaric acid in HCT-15 colon
cancer cells. World Journal of Gastroenterology 19 (43): 77267734. doi: 10.3748/wjg.v19.i43.7726.
Janicke B, Hegardt C, Krogh M, Onning G, Akesson B et al.
(2011). The antiproliferative effect of dietary fiber phenolic
compounds ferulic acid and p-coumaric acid on the cell cycle
of Caco-2 cells. Nutrition and Cancer 63 (4): 611-622. doi:
10.1080/01635581.2011.538486.
Jiang B, Zhao W, Shi M, Zhang J, Chen A et al. (2018). IDH1 Arg-132
mutant promotes tumor formation through down-regulating
p53. The Journal of Biological Chemistry 293 (25): 9747-9758.
doi: 10.1074/jbc.RA117.001385.
Johnson CM, Wei CM, Ensor JE, Smolenski DJ, Amos CI et al. (2013).
Meta-analyses of colorectal cancer risk factors. Cancer Causes
& Control 24 (6): 1207-1222. doi: 10.1007/s10552-013-0201-5.
Karacelik AA, Kucuk M, Iskefiyeli Z, Aydemir S, De Smet S et al.
(2015). Antioxidant components of Viburnum opulus L.
determined by on-line HPLC-UV-ABTS radical scavenging
and LC-UV-ESI-MS methods. Food Chemistry 175: 106-114.
doi: 10.1016/j.foodchem.2014.11.085.
Karakurt S, Adali O (2016). Tannic acid inhibits proliferation,
migration, invasion of prostate cancer and modulates drug
metabolizing and antioxidant enzymes. Anti-Cancer Agents in
Medicinal Chemistry 16 (6): 781-789. doi: 10.2174/187152061
6666151111115809.
Karakurt S, Semiz A, Celik G, Gencler-Ozkan AM, Sen A et al. (2016).
Contribution of ellagic acid on the antioxidant potential of
medicinal plant Epilobiumhirsutum. Nutrition and Cancer 68
(1): 173-183. doi: 10.1080/01635581.2016.1115092.

KARAKURT et al. / Turk J Biol
Kizilay F, Ulker V, Celik O, Ozdemir T, Cakmak O et al. (2019). The
evaluation of the effectiveness of Gilaburu (Viburnum opulus
L.) extract in the medical expulsive treatment of distal ureteral
stones. Turkish Journal of Urology 45: 63-69. doi: 10.5152/
tud.2019.23463.

Velioglu S (2006). Phenolic composition of European cranberrybush
(Viburnum opulus L.) berries and astringency removal of
its commercial juice. International Journal of Food Science
and Technology 41 (9): 1011-1015. doi: 10.1111/j.13652621.2006.01142.x.

Kwon JH, Jeong BK, Yoon YS, Yu CS, Kim J (2018). Utility of BRAF
VE1 immunohistochemistry as a screening tool for colorectal
cancer harboring BRAF V600E mutation. Journal of Pathology
and Translational Medicine 52 (3): 157-163. doi: 10.4132/
jptm.2018.03.28.

Wang D, Zhang Z, Li Y, Xu C, Yu Y et al. (2019). Adenomatous
polyposis coli gene mutations in 22 Chinese pedigrees with
familial adenomatous polyposis. Medical Science Monitor 25:
3796-3803. doi: 10.12659/MSM.913911.

Massague J (2008). TGFbeta in cancer. Cell 134 (2): 215-230. doi:
10.1016/j.cell.2008.07.001.
Moldovan B, David L, Vulcu A, Olenic L, Perde-Schrepler M et al.
(2017). In vitro and in vivo anti-inflammatory properties of
green synthesized silver nanoparticles using Viburnum opulus
L. fruits extract. Materials Science & Engineering C-Materials
for Biological Applications 79: 720-727. doi: 10.1016/j.
msec.2017.05.122.
Moldovan B, Ghic O, David L, Chisbora C (2012). The influence of
storage on the total phenols content and antioxidant activity of
the Cranberrybush (Viburnum opulus L.) fruits extract. Revista
De Chimie 63 (5): 463-464.
Namani A, Li J, Wang XJ, Tang X (2017). A review of compounds
for prevention of colorectal cancer. Current Pharmacology
Reports 3 (5): 221-231. doi: 10.1007/s40495-017-0101-6.
Russell W, Duthie G (2011). Plant secondary metabolites and gut
health: the case for phenolic acids. Proceedings of The Nutrition
Society 70 (3): 389-396. doi: 10.1017/S0029665111000152.
Sharma SH, Rajamanickam V, Nagarajan S (2018). Antiproliferative
effect of p-coumaric acid targets UPR activation by
downregulating Grp78 in colon cancer. Chemico-Biological
Interactions 291: 16-28. doi: 10.1016/j.cbi.2018.06.001.
Sheng S, Xie L, Wu Y, Ding M, Zhang T et al. (2019). MiR-144
inhibits growth and metastasis in colon cancer by downregulating SMAD4. Bioscience Reports 39 (3): BSR20181895.
doi: 10.1042/BSR20181895.
Slinkard K, Singleton VL (1977). Total phenol analyses: automation
and comparison with manual methods. American Journal of
Enology and Viticulture 28: 49-55.

Wu MS, Chien CC, Chang J, Chen YC (2019). Pro-apoptotic effect
of haem oxygenase-1 in human colorectal carcinoma cells via
endoplasmic reticular stress. Journal of Cellular and Molecular
Medicine 23 (8): 5692-5704. doi: 10.1111/jcmm.14482.
Yan W, Liu Z, Yang W, Wu G (2018). miRNA expression profiles
in Smad4-positive and Smad4-negative SW620 human
colon cancer cells detected by next-generation small RNA
sequencing. Cancer Management and Research 10: 5479-5490.
doi: 10.2147/CMAR.S178261.
Ying TH, Chen CW, Hsiao YP, Hung SJ, Chung JG et al. (2013).
Citric acid induces cell-cycle arrest and apoptosis of human
immortalized keratinocyte cell line (HaCaT) via caspase- and
mitochondrial-dependent signaling pathways. Anticancer
Research 33 (10): 4411-4420.
Yotova IY, Quan P, Leditznig N, Beer U, Wenzl R et al. (2011).
Abnormal activation of Ras/Raf/MAPK and RhoA/ROCKII
signalling pathways in eutopic endometrial stromal cells of
patients with endometriosis. Human Reproduction 26 (4):
885-897. doi: 10.1093/humrep/der010.
Zhang H, Yang X, Qin N, Li X, Yang H et al. (2015). Detection
and analysis of EGFR and KRAS mutation with lung
adenocarcinoma. Zhongguo Fei Ai Za Zhi 18 (11): 686-690 (in
Chinese). doi: 10.3779/j.issn.1009-3419.2015.11.05.
Zhang L, Shay JW (2017). Multiple roles of APC and its therapeutic
implications in colorectal cancer. Journal of the National
Cancer Institute 109 (8): djw332. doi: 10.1093/jnci/djw332.
Zhao M, Mishra L, Deng CX (2018). The role of TGF-beta/SMAD4
signaling in cancer. International Journal of Biological Sciences
14 (2): 111-123. doi: 10.7150/ijbs.23230.

Ulger H, Ertekin T, Karaca O, Canoz O, Nisari M et al. (2013). Influence
of gilaburu (Viburnum opulus) juice on 1,2-dimethylhydrazine
(DMH)-induced colon cancer. Toxicology and Industrial
Health 29 (9): 824-829. doi: 10.1177/0748233712445049.

263

